sellWeak cluster of 410b5-1 plan
Sorenson John Bradley sold $2.7M of BSX
EVP, Global Operations at BOSTON SCIENTIFIC CORP. 30,580 shares at an average of $87.66, traded Nov 8, 2024, filed Nov 12, 2024.
Warning score
30Value
$2.7M
30,580 shares
Holdings after
39,706
-44% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001225208-24-009878, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 8, 2024 | MOption exercise Common Stock10b5-1 | +17,362 | $24.55 | $426k | 70,286 | Nov 12, 2024 |
| Nov 8, 2024 | SOpen-market sale Common Stock10b5-1 | -30,580 | $87.66 | $2.7M | 39,706 | Nov 12, 2024 |
| Nov 8, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,362 | $0.00 | $0 | 0 | Nov 12, 2024 |
Related signals
Other insiders at BOSTON SCIENTIFIC CORP and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 20Weak | sell 410b5-1 | BSX BOSTON SCIENTIFIC CORP | Carruthers Wendy EVP, Human Resources | $634k | 6,983 | |
| 50Moderate | sell 4 | BSX BOSTON SCIENTIFIC CORP | Woodworth Emily SVP, Global Controller and CAO | $121k | 1,336 | |
| 50Moderate | sell 410b5-1 | BSX BOSTON SCIENTIFIC CORP | Butcher Arthur C EVP& Grp Pres, MedSurg & APAC | $1.3M | 14,010 | |
| 52Moderate | sell 5 | BSX BOSTON SCIENTIFIC CORP | LUDWIG EDWARD J director | $447k | 4,877 | |
| 30Weak | sell 310b5-1 | BSX BOSTON SCIENTIFIC CORP | Mahoney Michael F Chairman, President & CEO | $14M | 162,778 | |
| 19Weak | sell 310b5-1 | BSX BOSTON SCIENTIFIC CORP | Carruthers Wendy EVP, Human Resources | $589k | 6,983 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.